Skip to content

Vascular Abnormalities and Bleeding Diathesis

Endothelial Dysfunction Leads to Bleeding Diathesis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04553172
Enrollment
5
Registered
2020-09-17
Start date
2016-03-01
Completion date
2019-04-01
Last updated
2021-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding Diathesis

Keywords

mucocutaneous bleeding, surgery bleeding outcomes

Brief summary

Inherited bleeding disorders (IBD) consist of a heterogeneous group of diseases including coagulation and/or platelets defects and more rarely vascular dysfunctions. A family of four patients suffering from unexplained excessive bleeding has been followed clinically in France for many years. Recently, whole exome sequencing (WES) of DNA allowed the identification of a heterozygous genetic variant which segregated to family members with bleeding diathesis. The aim of the study was to better characterize the phenotype by studying VWF and platelets in affected family members ultimately contributing to the pathogenesis of a bleeding diathesis.

Detailed description

As explained in the brief summary, whole exome sequencing (WES) of DNA was performed in a family of four patients suffering from unexplained excessive bleeding. It allowed the identification of a variant which segregated to family members with bleeding diathesis. Firstly, in vitro, functional analyses were performed in primary human endothelial cells. Then, in-vivo analysis have to be performed on affected patients. The four related patients suffering from excessive bleeding have been followed clinically in France for many years. During the follow-up of three of these affected patients, biological studies are planned. Biological assays include: * Conventional assessment of primary haemostasis: platelet count, platelet aggregation, functional and antigen measurement of von Willebrand factor. * Specific testing: Von Willebrand factor multimeric profile, immunolabeling of platelets. Conventional assessment is part of the conventional follow-up of patients with inherited bleeding disorder. It will not require any additional blood sample. For specific testing and after informed consent, fresh blood samples of patients will be collected in 1/10 volume of acid-citrate-dextrose and centrifuged for 10 min at 200 g to obtain Platelet-rich plasma (PRP) for functional analysis of platelets and Platelet-poor plasma for the multimerization state of von Willebrand factor. Then, the results will be compared to the in-vitro findings.

Interventions

None listed

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
FAMILY_BASED
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

\- members of the family

Exclusion criteria

\- patient who refused to participate

Design outcomes

Primary

MeasureTime frameDescription
platelet count1 dayautomatic count of platelet
platelet aggregation1 dayautomated assay using adenosine diphosphate (ADP), arachidonic acid (AA) agonists
VWF (von Willebrand factor)1 dayactivity/antigen levels measurements

Secondary

MeasureTime frameDescription
VWF mutimerization status1 daymultimer distribution
immunostaining of platelets2 to 3 daysfixed platelet studies coverslips are challenged with a panel of primary antibodies for immunofluorescence staining

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026